Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px
Document › Details

NLC Ventures Netherlands B.V.. (2/2/24). "Press Release: NLC Health Ventures and BioScience Valuation (BSV) Announce Strategic Collaboration". Amsterdam.

Organisations Organisation NLC Ventures Netherlands B.V. (NLC Health Ventures)
  Group NLC Ventures (Group)
  Organisation 2 Bioscience Valuation BSV GmbH
Products Product venture capital
  Product 2 biopharmaceutical
Persons Person Heltovics, Gábor (NLC Ventures 202402 Partner formerly Druggability Technologies + Solvo Biotechnology)
  Person 2 Greuel, Joachim M. (Bioscience Valuation BSV GmbH 20203 Managing Director)

NLC Health Ventures and BioScience Valuation (BSV) initiate a strategic collaboration to accelerate venture creation through best-in-class due diligence of early-stage bio-pharmaceutical assets.

NLC Health Ventures operates within the inherent complexity of bio-pharmaceutical innovations that require comprehensive risk assessment and corresponding corporate development strategies. BioScience Valuation is renowned for its excellence in evidence-based scientific, financial, and economic evaluations and modeling for the bio-pharmaceutical industry.

“We are very excited to partner with BioScience Valuation” , said Gábor Heltovics, Partner at NLC Health Ventures. “In our pursuit of groundbreaking innovations, this collaboration ensures that our bio-pharmaceutical ventures are of the highest scientific standards with excellent commercial viability.”

Joachim Greuel, Co-Founder and Managing Director at BioScience Valuation – said: “We are thrilled to collaborate with the world-class, leading global venture builder NLC Health Ventures in order to found and develop life sciences start-ups that have the potential to significantly improve patients’ lives. NLC Health Ventures is known for their comprehensive and diligent scientific assessments of investment opportunities, and we are proud to further strengthen NLC’s investment decision processes.”


NLC Health Ventures is the leading European early-stage healthcare investor and the world’s largest venture builder in healthtech. NLC identifies the best healthcare inventions and brings them to market, acting as the connecting link between technology innovation and entrepreneurship in biotech, medtech, and digital industries. NLC collaborates with academic and healthcare institutions and corporations. With its growing team of more than 80 professionals, four captive funds, and over 110 portfolio ventures built across 11 countries, we bring science to life and make the early-stage investible.


BioScience Valuation is a team of seasoned physicians, scientists, and finance experts with over 20 years of experience in pharma, biotech, and medtech. The team specializes in scientific as well as commercial assessments and provides evidence-based valuations, advising start-ups, maturing companies, and fully integrated firms in making value-driven investment decisions. BioScience Valuation’s comprehensive approach extends to asset prioritization, business strategy optimization, value-centric company reorganization, and negotiations involving acquisitions, licensing deals, financings, and exits.


For any biotech-related inquiries and collaboration opportunities, please contact Lydia Kalafateli at

For any media-related requests, please contact Anne Reijns at

For any inquiry related to the assessment of investment opportunities, please contact Merlin M. Greuel at or find us on LinkedIn

Record changed: 2024-03-14


Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for NLC Ventures (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top